310 related articles for article (PubMed ID: 22055975)
1. Long-term progression of Alzheimer's disease in patients under antidementia drugs.
Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Gardette V; Coley N; Cantet C; Gauthier S; Ousset PJ; Vellas B;
Alzheimers Dement; 2011 Nov; 7(6):579-92. PubMed ID: 22055975
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study.
Cortes F; Nourhashémi F; Guérin O; Cantet C; Gillette-Guyonnet S; Andrieu S; Ousset PJ; Vellas B;
Alzheimers Dement; 2008 Jan; 4(1):22-9. PubMed ID: 18631947
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
4. Predicting disease progression in Alzheimer's disease: the role of neuropsychiatric syndromes on functional and cognitive decline.
Palmer K; Lupo F; Perri R; Salamone G; Fadda L; Caltagirone C; Musicco M; Cravello L
J Alzheimers Dis; 2011; 24(1):35-45. PubMed ID: 21157019
[TBL] [Abstract][Full Text] [Related]
5. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
Cortes F; Portet F; Touchon J; Vellas B
J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
[TBL] [Abstract][Full Text] [Related]
6. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
[TBL] [Abstract][Full Text] [Related]
7. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
[TBL] [Abstract][Full Text] [Related]
8. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
9. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
[TBL] [Abstract][Full Text] [Related]
12. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.
Suh GH; Ju YS; Yeon BK; Shah A
Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138
[TBL] [Abstract][Full Text] [Related]
13. Neuropsychological screening performance and the association with activities of daily living and instrumental activities of daily living in dementia: baseline and 18- to 24-month follow-up.
Monaci L; Morris RG
Int J Geriatr Psychiatry; 2012 Feb; 27(2):197-204. PubMed ID: 22223145
[TBL] [Abstract][Full Text] [Related]
14. Weight loss and rapid cognitive decline in community-dwelling patients with Alzheimer's disease.
Soto ME; Secher M; Gillette-Guyonnet S; Abellan van Kan G; Andrieu S; Nourhashemi F; Rolland Y; Vellas B
J Alzheimers Dis; 2012; 28(3):647-54. PubMed ID: 22045479
[TBL] [Abstract][Full Text] [Related]
15. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
[TBL] [Abstract][Full Text] [Related]
16. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
17. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden].
Hirono N; Tsukamoto N; Inoue M; Moriwaki Y; Mori E
No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367
[TBL] [Abstract][Full Text] [Related]
18. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
19. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease risk factors and progression of Alzheimer's disease.
Abellan van Kan G; Rolland Y; Nourhashémi F; Coley N; Andrieu S; Vellas B
Dement Geriatr Cogn Disord; 2009; 27(3):240-6. PubMed ID: 19246908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
